



**Futura Medical**  
Advanced Transdermal Technology

# Investor fact sheet

March 2018

## Futura Medical plc

Surrey Technology Centre  
40 Occam Road  
The Surrey Research Park  
Guildford, Surrey, GU2 7YG

Tel: 01483 685670

info@futuramedical.com

www.futuramedical.com

## Management

### Chairman

**John Clarke** - Extensive experience of the Healthcare sector having worked at GSK for more than 35 years.

### Chief Executive

**James Barder** - Over 25 years of experience in setting up, managing and running companies.

### Executive Director -Head of R&D

**Ken James** - Over 40 years' experience in research and development.

### Finance Director and Chief Operating Officer

**Angela Hildreth** - Over 15 years' experience in finance.

### Non Executive Director

**Jonathan Freeman** - Over 25 years' experience in the financial services sector, guidance on City regulatory matters, corporate finance and investor relations.

## Share statistics

(as at close 13 March 2018)

Share price: 42.50p

Shares in issue (m): 120.86

Market cap (£m): 51.36

Year end: 31 December

Sector: Pharmaceuticals

Activities: Advanced transdermal technology

Broker/NOMAD: N+1 Singer



## What we do

Futura's innovation strategy applies advanced science to develop products with compelling commercial potential using its advanced proprietary transdermal technology, DermaSys<sup>®</sup>. We have five products in our development pipeline for sexual healthcare and pain relief. We continue to evaluate further product opportunities utilising our DermaSys<sup>®</sup> technology.

## Strategy

- **Advanced Transdermal Technology:** Offering innovative delivery of proven compounds through the skin to improve their performance or to address new indications.
- **Controlled Development Risk:** Using only approved compounds to control the risk profile.
- **Strong Intellectual Property:** Developing products where the Group can secure strong patent protection.
- **Commercialisation:** Out-licensing products to leading healthcare companies which offer the optimum potential financial return.

## Commercial Partnerships

Futura has several agreements with leading pharmaceutical and healthcare groups for the distribution of its product CSD500 and has signed its first agreement for the distribution of TPR100.

## DermaSys<sup>®</sup> Technology

Futura has developed a highly efficient and proprietary delivery technology, DermaSys<sup>®</sup>, for the absorption of active molecules through the skin. DermaSys<sup>®</sup> is a versatile and bespoke technology in that it can be tailored to suit the specific active compound being used and the therapeutic indication. Such targeted delivery offers an optimised profile in terms of dose, onset time and duration of effect as well as an improved safety profile through lower systemic uptake and the reduced risk of side effects.

## Major shareholders - March 2018

Lombard Odier Asset Mgmt	18.9%	WT Lamb Investments	3.9%
Octopus Asset Mgmt	7.9%	Medinvest	3.5%
RA Lamb	7.9%		

## Key financial data

	Year ended 31 Dec 17	Year ended 31 Dec 16	Year ended 31 Dec 15
	(£'000)	(£'000)	(£'000)
Revenue/Income	363	170	29
R&D	(4,100)	(3,510)	(4,778)
Other administrative costs	(1,118)	(1,215)	(1,368)
Operating loss	(4,856)	(4,554)	(6,117)
Finance income	19	15	38
Tax credit receivable	936	842	997
Loss after tax	(3,900)	(3,697)	(5,081)
Net cash	8,363	12,353	4,188

## Recent significant news flow

- 14 Mar18 Preliminary Results for the year ended 31 December 2017
- 13 Mar18 Positive Interim Data from MED2002 PK Study
- 20 Feb18 Directorate Change
- 15 Feb18 Notification of Preliminary Results
- 04 Jan18 Publication of Positive MED2002 Clinical Data
- 29 Nov 17 MED2002 PK Study Commences

## 6 month share price performance



## Our Pipeline

### Sexual Healthcare



#### CSD500

Description: Condom containing an erectogenic gel  
 Status: Launched in Saudi Arabia. Further launches expected in 2018

#### MED2002

Description: Topical gel for erectile dysfunction  
 Status: Final Phase III programme and out-licensing discussions ongoing



### Pain Relief



#### TPR100

Description: Topical diclofenac pain relief gel  
 Status: First licensing agreement signed. Further discussions ongoing



#### TIB200

Description: Topical ibuprofen pain relief gel  
 Status: Out-licensing discussions ongoing



#### SPR300

Description: Topical methyl salicylate pain relief gel  
 Status: Potential follow on product to TIB200 / TPR100



## Investor Relations Contacts

### Buchanan Communications

Mark Court  
 markc@buchanan.uk.com  
 Telephone: +44 (0)20 7466 5000

### Futura Medical plc

James Barder, Chief Executive  
 james.barder@futura-medical.com  
 Telephone: +44 (0)1483 685 670

Angela Hildreth, Finance Director and COO  
 angela.hildreth@futura-medical.com  
 Telephone: +44 (0)1483 685 670

